1
|
Tang N, Zhang Q, Fang S, Han X, Wang Z. Anti-tumor activity of high-dose EGFR tyrosine kinase inhibitor and sequential docetaxel in wild type EGFR non-small cell lung cancer cell nude mouse xenografts. Oncotarget 2018; 8:9134-9143. [PMID: 27852073 PMCID: PMC5354720 DOI: 10.18632/oncotarget.13327] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/29/2016] [Accepted: 11/07/2016] [Indexed: 01/24/2023] Open
Abstract
Treatment of non-small-cell lung cancer (NSCLC) with wild-type epidermal growth factor receptor (EGFR) is still a challenge. This study explored antitumor activity of high-dose icotinib (an EGFR tyrosine kinase inhibitor) plus sequential docetaxel against wild-type EGFR NSCLC cells-generated nude mouse xenografts. Nude mice were subcutaneously injected with wild-type EGFR NSCLC A549 cells and divided into different groups for 3-week treatment. Tumor xenograft volumes were monitored and recorded, and at the end of experiments, tumor xenografts were removed for Western blot and immunohistochemical analyses. Compared to control groups (negative control, regular-dose icotinib [IcoR], high-dose icotinib [IcoH], and docetaxel [DTX]) and regular icotinib dose (60 mg/kg) with docetaxel, treatment of mice with a high-dose (1200 mg/kg) of icotinib plus sequential docetaxel for 3 weeks (IcoH-DTX) had an additive effect on suppression of tumor xenograft size and volume (P < 0.05). Icotinib-containing treatments markedly reduced phosphorylation of EGFR, mitogen activated protein kinase (MAPK), and protein kinase B (Akt), but only the high-dose icotinib-containing treatments showed an additive effect on CD34 inhibition (P < 0.05), an indication of reduced microvessel density in tumor xenografts. Moreover, high-dose icotinib plus docetaxel had a similar effect on mouse weight loss (a common way to measure adverse reactions in mice), compared to the other treatment combinations. The study indicate that the high dose of icotinib plus sequential docetaxel (IcoH-DTX) have an additive effect on suppressing the growth of wild-type EGFR NSCLC cell nude mouse xenografts, possibly through microvessel density reduction. Future clinical trials are needed to confirm the findings of this study.
Collapse
Affiliation(s)
- Ning Tang
- Department of Oncology, Shandong Cancer Hospital and Institute, Jinan, China
| | - Qianqian Zhang
- Department of Jining Number One People's Hospital, Jinan, China
| | - Shu Fang
- Department of Oncology, Shandong Cancer Hospital and Institute, Jinan, China
| | - Xiao Han
- Department of Oncology, Shandong Cancer Hospital and Institute, Jinan, China
| | - Zhehai Wang
- Department of Oncology, Shandong Cancer Hospital and Institute, Jinan, China
| |
Collapse
|
2
|
Tian Y, Zheng W, Ge H, Wang Y, Zha N, Huang S, Guo Z. Molecular characteristics of multifocal invasive mucinous adenocarcinoma of the lung: Report of a rare case. Thorac Cancer 2017; 8:710-713. [PMID: 28851076 PMCID: PMC5668484 DOI: 10.1111/1759-7714.12495] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/07/2017] [Revised: 07/22/2017] [Accepted: 07/22/2017] [Indexed: 01/04/2023] Open
Abstract
Invasive mucinous adenocarcinoma (IMA) is an uncommon entity in the lung, with a poor prognosis. Multifocal IMA of the lung is even more unusual, and there is little experience with effective treatments. Herein, we present a case of multifocal IMA diagnosed in a 36 year‐old man by video‐assisted thoracoscopic surgery. A right middle lobe and a nodule in the right upper lobe were resected, as were mediastinal lymph nodes, leaving behind an autonomous right lower lobe nodule. To explore the feasibility of molecular treatment, next‐generation sequencing of genetic mutations was performed after four cycles of chemotherapy (pemetrexed + cisplatin). Ultimately, a KIAA1468‐RET fusion gene was detected at a disproportionate level (~67.3%), indicating that targeted therapy may be efficacious in treating this disease.
Collapse
Affiliation(s)
- Yan Tian
- Department of Hyperbaric Oxygen, The Affiliated Hospital of Inner Mongolia Medical University, Hohhot, China
| | - Wenqi Zheng
- Laboratory of Surgery, The Affiliated Hospital of Inner Mongolia Medical University, Hohhot, China
| | - Huijing Ge
- Department of Thoracic Surgery, The Affiliated Hospital of Inner Mongolia Medical University, Hohhot, China
| | - Yufei Wang
- Department of Thoracic Surgery, The Affiliated Hospital of Inner Mongolia Medical University, Hohhot, China
| | - Nashunbayaer Zha
- Department of Thoracic Surgery, The Affiliated Hospital of Inner Mongolia Medical University, Hohhot, China
| | - Shaojun Huang
- Department of Thoracic Surgery, The Affiliated Hospital of Inner Mongolia Medical University, Hohhot, China
| | - Zhanlin Guo
- Department of Thoracic Surgery, The Affiliated Hospital of Inner Mongolia Medical University, Hohhot, China
| |
Collapse
|
3
|
KRAS mutation-induced upregulation of PD-L1 mediates immune escape in human lung adenocarcinoma. Cancer Immunol Immunother 2017; 66:1175-1187. [PMID: 28451792 PMCID: PMC5579171 DOI: 10.1007/s00262-017-2005-z] [Citation(s) in RCA: 198] [Impact Index Per Article: 28.3] [Reference Citation Analysis] [Abstract] [Key Words] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/24/2016] [Accepted: 04/18/2017] [Indexed: 12/28/2022]
Abstract
It was reported that PD-L1 expression was correlated with genetic alterations. Whether PD-L1 was regulated by mutant Kirsten rat sarcoma viral oncogene homolog (KRAS) in non-small-cell lung cancer (NSCLC) and the underlying molecular mechanism were largely unknown. In this study, we investigated the correlation between PD-L1 expression and KRAS mutation and the functional significance of PD-1/PD-L1 blockade in KRAS-mutant lung adenocarcinoma. We found that PD-L1 expression was associated with KRAS mutation both in the human lung adenocarcinoma cell lines and tissues. PD-L1 was up-regulated by KRAS mutation through p-ERK but not p-AKT signaling. We also found that KRAS-mediated up-regulation of PD-L1 induced the apoptosis of CD3-positive T cells which was reversed by anti-PD-1 antibody (Pembrolizumab) or ERK inhibitor. PD-1 blocker or ERK inhibitor could recover the anti-tumor immunity of T cells and decrease the survival rates of KRAS-mutant NSCLC cells in co-culture system in vitro. However, Pembrolizumab combined with ERK inhibitor did not show synergistic effect on killing tumor cells in co-culture system. Our study demonstrated that KRAS mutation could induce PD-L1 expression through p-ERK signaling in lung adenocarcinoma. Blockade of PD-1/PD-L1 pathway may be a promising therapeutic strategy for human KRAS-mutant lung adenocarcinoma.
Collapse
|
4
|
Ferretti GR, Reymond E, Delouche A, Sakhri L, Jankowski A, Moro-Sibilot D, Lantuejoul S, Toffart AC. Personalized chemotherapy of lung cancer: What the radiologist should know. Diagn Interv Imaging 2016; 97:287-96. [PMID: 26857787 DOI: 10.1016/j.diii.2015.11.013] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/07/2015] [Revised: 11/05/2015] [Accepted: 11/05/2015] [Indexed: 11/24/2022]
Abstract
Lung cancer is the leading cause of deaths due to cancer in France. More than half of lung cancers are discovered at an advanced-stage. New anticancer treatment strategies (i.e., the so-called personalized or targeted therapy) have recently been introduced and validated for non-small-cell lung cancer (NSCLC), in addition to or in association with standard chemotherapy. Personalized therapy includes tyrosine kinase inhibitors (TKIs), antiangiogenic treatments and immunotherapy. Because these treatments may be responsible for atypical thoracic adverse effects and responses as compared to standard chemotherapy, RECIST 1.1 criteria may be inadequate to evaluate the responses to these agents. The goal of this article was to review personalized treatment strategies for NSCLC, to consider the therapy-specific responses and thoracic complications induced by these new therapeutic agents and finally to discuss future directions for the personalized assessment of tumor response.
Collapse
Affiliation(s)
- G R Ferretti
- Clinique universitaire de radiologie et imagerie médicale, CHU A.-Michallon, BP 217, 38043 Grenoble cedex 9, France; Inserm U 823, institut A.-Bonniot, 38000 Grenoble, France; Université Grenoble-Alpes, 38000 Grenoble, France.
| | - E Reymond
- Clinique universitaire de radiologie et imagerie médicale, CHU A.-Michallon, BP 217, 38043 Grenoble cedex 9, France; Inserm U 823, institut A.-Bonniot, 38000 Grenoble, France; Université Grenoble-Alpes, 38000 Grenoble, France
| | - A Delouche
- Clinique universitaire de radiologie et imagerie médicale, CHU A.-Michallon, BP 217, 38043 Grenoble cedex 9, France
| | - L Sakhri
- Clinique universitaire de pneumologie, pôle d'oncologie, CHU A.-Michallon, 38043 Grenoble, France
| | - A Jankowski
- Clinique universitaire de radiologie et imagerie médicale, CHU A.-Michallon, BP 217, 38043 Grenoble cedex 9, France
| | - D Moro-Sibilot
- Inserm U 823, institut A.-Bonniot, 38000 Grenoble, France; Université Grenoble-Alpes, 38000 Grenoble, France; Clinique universitaire de pneumologie, pôle d'oncologie, CHU A.-Michallon, 38043 Grenoble, France
| | - S Lantuejoul
- Inserm U 823, institut A.-Bonniot, 38000 Grenoble, France; Université Grenoble-Alpes, 38000 Grenoble, France; Département d'anatomo-cytologie pathologie, CHU A.-Michallon, 38043 Grenoble, France
| | - A C Toffart
- Inserm U 823, institut A.-Bonniot, 38000 Grenoble, France; Université Grenoble-Alpes, 38000 Grenoble, France; Clinique universitaire de pneumologie, pôle d'oncologie, CHU A.-Michallon, 38043 Grenoble, France
| |
Collapse
|
5
|
Meert AP, Ameye L, Leclercq N, Paesmans M, Remmelink M, Sculier JP, Berghmans T. [Difficulties and limitations in conducting translational research in thoracic oncology. A practical example]. Rev Mal Respir 2016; 33:594-9. [PMID: 26777111 DOI: 10.1016/j.rmr.2015.10.744] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/29/2015] [Accepted: 10/09/2015] [Indexed: 11/26/2022]
Abstract
INTRODUCTION In a first study, we identified signatures of 3 mRNAs (semaphorin 3D [SEMA3D], cytokeratin 16 [KRT16] and UL16 binding protein 2 [ULBP2]) associated to response to a cisplatin-vinorelbin chemotherapy and to survival of advanced non-small cell lung cancers (NSCLC). MATERIAL AND METHODS The aim of this study was to develop immunohistochemistry tests for KRT16, ULBP2 and SEMA3D and to test proteins expression for prediction of response and survival in biopsies of the same patients. RESULTS We were not able to reproduce by the protein expression study the signature predicting response to chemotherapy in advanced NSCLC. CONCLUSION We highlight the difficulties of translational research in thoracic oncology emphasizing the complexity in obtaining adequate tissue samples and the difficulties in conduction and transposing in routine practice high throughput technique for transcriptomic analyses.
Collapse
Affiliation(s)
- A-P Meert
- Service des soins intensifs, urgences oncologiques et oncologie thoracique, institut Jules-Bordet, université libre de Bruxelles, 1, rue Héger-Bordet, 1000 Bruxelles, Belgique.
| | - L Ameye
- Data centre, institut Jules-Bordet, université libre de Bruxelles, Bruxelles, Belgique
| | - N Leclercq
- Service des soins intensifs, urgences oncologiques et oncologie thoracique, institut Jules-Bordet, université libre de Bruxelles, 1, rue Héger-Bordet, 1000 Bruxelles, Belgique
| | - M Paesmans
- Data centre, institut Jules-Bordet, université libre de Bruxelles, Bruxelles, Belgique
| | - M Remmelink
- Service d'anatomopathologie, hôpital Erasme, université libre de Bruxelles, Bruxelles, Belgique
| | - J-P Sculier
- Service des soins intensifs, urgences oncologiques et oncologie thoracique, institut Jules-Bordet, université libre de Bruxelles, 1, rue Héger-Bordet, 1000 Bruxelles, Belgique
| | - T Berghmans
- Service des soins intensifs, urgences oncologiques et oncologie thoracique, institut Jules-Bordet, université libre de Bruxelles, 1, rue Héger-Bordet, 1000 Bruxelles, Belgique
| |
Collapse
|
6
|
Hantraye B, Leroux A, Clere N. Les inhibiteurs de tyrosine kinase. ACTUALITES PHARMACEUTIQUES 2015. [DOI: 10.1016/j.actpha.2015.10.006] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
7
|
Xie WY, Zhou XD, Li Q, Chen LX, Ran DH. Acid-induced autophagy protects human lung cancer cells from apoptosis by activating ER stress. Exp Cell Res 2015; 339:270-9. [DOI: 10.1016/j.yexcr.2015.11.005] [Citation(s) in RCA: 30] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/04/2015] [Revised: 10/22/2015] [Accepted: 11/06/2015] [Indexed: 02/04/2023]
|
8
|
Guibert N, Noel-Savina E, Mazières J. Perspective of a pulmonologist: what might we expect and what do we need to know? Lung Cancer 2015. [DOI: 10.1183/2312508x.10011014] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
|